戻る
Coherus Oncology Inc (CHRS)価格
CHRS 株価推移チャート
CHRS 収入
Coherus Oncology Inc
$1.6
-3.61%
$-0.05
終値： Jan 16, 16:00:00 GMT-5
$1.6
0%
$0
アフターマーケット：Jan 16, 20:00:00 GMT-5
最新の利益結果: Q3 '25
報告済み: 2025-11-06
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
CHRSの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Coherus Oncology Inc CHRSの前四半期の収益はどうでしたか？
Coherus Oncology Incの収益見積もりはいくらですか？
Coherus Oncology Incの収益品質スコアはどれくらいですか？
Coherus Oncology Incはいつ収益を報告しますか？
Coherus Oncology Incの予想収益はいくらですか？
Coherus Oncology Incは収益予想を上回りましたか？
主要データ
前終値
$1.66
始値
$1.67
当日レンジ
$1.59 - $1.67
52週レンジ
$0.71 - $1.89
取引高
986.0K
平均取引高
1.1M
1株当たり利益(TTM)
1.33
配当利回り
--
時価総額
$193.3M
CHRSとは何ですか？
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 161 full-time employees. The company went IPO on 2014-11-06. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).